Physician profile
Min Gao
NPI 1134155005
$1,188.66
in general payments reported to CMS, 2019-2025
17 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $155 · 2023: $112 · 2024: $274 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $154.58 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $153.85 | 2023-2025 | Farxiga, Lokelma, Breztri |
| Novo Nordisk INC | $141.84 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $121.38 | 2019-2025 | |
| Mdd US Operations, LLC | $107.36 | 2019 | |
| Amgen INC. | $102.10 | 2024 | Evenity |
| Amarin Pharma, INC. | $97.42 | 2019 | |
| Pacira Therapeutics, INC. | $64.93 | 2019 | |
| Biogen, INC. | $51.17 | 2025 | Leqembi |
| Ucb, INC. | $44.11 | 2024 | Fintepla |
| Novartis Pharmaceuticals Corporation | $41.03 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $28.81 | 2024 | Austedo Xr |
| Dexcom, INC. | $21.06 | 2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.69 | 2025 | Gemtesa |
| Lilly USA, LLC | $15.05 | 2024 | Zepbound, Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.32 | 2025 | Rexulti |
| Allergan, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.